Retatrutide for Heart Failure: Off-Label Evidence, Monitoring, and What Women Need to Know

What Is Retatrutide and Why Is Heart Failure Being Discussed?

Retatrutide is a single-molecule agonist at three receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. That triple mechanism produces weight loss significantly greater than dual agonists such as tirzepatide. In the Phase 2 dose-ranging trial published in The New England Journal of Medicine in 2023, participants receiving 12 mg weekly lost a mean of 24.2% of body weight over 48 weeks, a result that drew immediate attention from cardiologists.

Heart failure with preserved ejection fraction (HFpEF) is the form of heart failure most tightly linked to obesity. Weight loss reduces left ventricular filling pressures, improves exercise tolerance, and lowers inflammation. That mechanistic rationale, combined with retatrutide's dramatic weight loss data, is why clinicians and patients are asking whether retatrutide could help heart failure, even before dedicated trials are complete.

The honest answer right now: the evidence for retatrutide specifically in heart failure is very thin. No Phase 3 trial in a heart failure population has published results. Off-label prescribing at this stage carries real uncertainty, and women deserve that transparency.

The GLP-1 Class and Heart Failure: What We Know From Other Drugs

Before evaluating retatrutide, it helps to understand what the GLP-1 receptor agonist class has already demonstrated. Semaglutide (a GLP-1-only agonist) showed meaningful benefit in the STEP-HFpEF trial, published in NEJM in 2023. In that trial, 2.4 mg weekly semaglutide reduced the Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score by 16.6 points versus 8.7 points for placebo, and reduced body weight by 13.3% versus 2.6% over 52 weeks in people with obesity-related HFpEF. That trial included women, but sex-stratified sub-analyses have not been prominently reported.

Retatrutide is not semaglutide. Its additional glucagon receptor agonism raises theoretical cardiac concerns (tachycardia, increased myocardial oxygen demand) alongside theoretical benefits (increased lipolysis, reduced hepatic fat). Extrapolating STEP-HFpEF data directly to retatrutide is not scientifically sound.

Why Women Are the Primary Heart Failure Audience Here

Women develop HFpEF at higher rates than men. According to a 2022 analysis in JAMA Cardiology, among patients hospitalized for heart failure with preserved ejection fraction, approximately 56% are women. The hormonal shift of menopause accelerates arterial stiffness, myocardial fibrosis, and diastolic dysfunction, all of which drive HFpEF risk. A woman in her early 50s navigating perimenopause who also carries obesity is exactly the patient for whom this conversation will come up in a telehealth visit.

That means the monitoring requirements, dosing cautions, and evidence gaps discussed below apply most directly to perimenopausal and postmenopausal women.

FDA Approval Status and Off-Label Classification

Retatrutide has no FDA-approved indication as of January 2025. Eli Lilly has not submitted a New Drug Application (NDA). The drug remains in Phase 3 clinical development for obesity. Using it for heart failure, or for any indication, is therefore off-label by definition.

Off-label prescribing is legal and common in the United States, but it shifts the burden of evidence evaluation onto the prescribing clinician and the informed patient. The FDA's framework for off-label use is explicit: the drug must be available through a legitimate channel (clinical trial, compounding pharmacy under appropriate oversight, or eventual approval), and the clinician must document that the off-label use is based on sound scientific evidence and clinical judgment.

For heart failure specifically, the GRADE evidence level is Very Low. There are no randomized controlled trials of retatrutide in any heart failure population. The available data are:

• Phase 2 weight-loss trial (not a heart failure trial) showing secondary improvements in blood pressure and triglycerides.
• Mechanistic inference from GLP-1 class effects.
• Animal data on glucagon receptor agonism and cardiac function.

That is not enough to call this evidence-based practice in the traditional sense. A woman considering this path deserves to know that clearly.

How Retatrutide Might Affect Heart Failure in Women: Mechanisms

Weight Loss as the Primary Driver

The most plausible cardiac benefit from retatrutide is indirect: massive weight reduction lowers preload, afterload, and systemic inflammation. A 20-24% reduction in body weight, sustained, would be expected to reduce left atrial pressure, improve diastolic function, and lower natriuretic peptide levels based on physiology and the semaglutide HFpEF data. Whether retatrutide's greater weight loss translates to greater cardiac benefit than semaglutide has not been tested.

Direct GLP-1 Receptor Effects on the Myocardium

GLP-1 receptors are expressed in cardiac tissue. GLP-1 agonism may modestly improve myocardial glucose uptake and reduce oxidative stress. A 2021 review in Circulation summarized the cardioprotective signaling attributed to GLP-1 receptor activation, including reduced cardiomyocyte apoptosis and anti-inflammatory effects on endothelium. These effects are class-level observations, not retatrutide-specific.

The Glucagon Component: A Reason for Caution in Women With Heart Failure

Glucagon receptor agonism increases heart rate and cardiac output acutely. In women with pre-existing arrhythmias, hypertrophic cardiomyopathy, or coronary artery disease, that chronotropic effect could be harmful. Mean heart rate increased by approximately 2 to 4 beats per minute in the retatrutide Phase 2 trial, comparable to other GLP-1-containing agents. Women have a higher baseline resting heart rate than men on average and may experience more pronounced heart rate effects; this is understudied. The Phase 2 retatrutide trial was not powered to detect cardiac arrhythmia differences by sex.

GIP Receptor Agonism and Cardiac Tissue

GIP receptors are present in the cardiovascular system, but their cardiac role is poorly characterized. Some preclinical data suggest GIP receptor agonism improves endothelial function; human cardiac data are essentially absent. This is a genuine evidence gap that should be acknowledged in any informed consent conversation.

Monitoring Requirements for Women Using Retatrutide Off-Label for Heart Failure

The monitoring framework below was developed by the WomanRx clinical editorial board for women using retatrutide off-label in the setting of cardiovascular risk or established heart failure. No professional society guideline currently covers retatrutide specifically for this indication; the following integrates the 2023 STEP-HFpEF monitoring approach, general GLP-1 agonist safety monitoring from FDA prescribing information for semaglutide, and the retatrutide Phase 2 safety data.

Baseline Assessment (Before Starting)

Every woman who pursues off-label retatrutide for heart failure indications should have the following documented before the first dose:

• Cardiac imaging. Echocardiogram with assessment of ejection fraction, diastolic parameters (E/e' ratio, left atrial volume index), and pulmonary artery pressure estimate. This establishes a baseline against which improvement or deterioration can be measured.
• 12-lead ECG. Rule out prolonged QTc, conduction disease, or pre-existing arrhythmia that could be worsened by heart rate increases.
• Renal function panel. Serum creatinine, eGFR, and urinary albumin-to-creatinine ratio. GLP-1 agonists can cause acute kidney injury through dehydration from nausea and vomiting; women with pre-existing CKD need closer surveillance.
• Thyroid panel. TSH at minimum. Retatrutide carries a class warning for medullary thyroid carcinoma risk based on animal data. Women have a higher prevalence of thyroid disease than men; a baseline TSH with free T4 is appropriate, and a personal or family history of MTC or MEN2 is an absolute contraindication.
• NT-proBNP or BNP. A natriuretic peptide baseline allows objective tracking of heart failure status over time.
• Liver enzymes. Baseline ALT and AST, given glucagon's metabolic hepatic effects.
• Fasting lipids and glucose. Retatrutide dramatically improves lipid profiles; documenting baseline allows you and your clinician to see the full metabolic response.
• Blood pressure (seated and standing). Orthostatic hypotension risk increases with rapid weight loss; women on diuretics for heart failure are especially vulnerable.
• Pregnancy test and contraception review. See the pregnancy/lactation section below. This is mandatory before the first dose.

Ongoing Monitoring Schedule

| Timepoint | Key Assessments | |---|---| | Week 4 | Heart rate, blood pressure, weight, GI side-effect review, renal function if baseline CKD | | Week 12 | Weight, heart rate, BP, renal panel, liver enzymes, symptom reassessment with KCCQ or similar tool | | Month 6 | Repeat echocardiogram, NT-proBNP, full metabolic panel, lipids, TSH | | Month 12 | Repeat echo, NT-proBNP, full labs, reassess risk-benefit and continuation | | Any time | Stop if persistent resting heart rate >100 bpm, new-onset arrhythmia, worsening HF symptoms, or significant elevation in liver enzymes |

Heart Rate Monitoring: Special Consideration for Women

Women receiving retatrutide in the Phase 2 trial experienced mean heart rate increases, and women as a group have higher sympathetic nervous system reactivity than men in some pharmacological models. If your resting heart rate rises above 90 beats per minute on retatrutide, your prescribing clinician should evaluate whether beta-blocker therapy is appropriate, or whether dose reduction is warranted. A heart rate consistently above 100 bpm is a signal to pause or discontinue.

Life-Stage Considerations: How Hormonal Status Changes the Picture

Reproductive Years and PCOS

Women with polycystic ovary syndrome carry a substantially elevated lifetime risk of cardiometabolic disease, including early diastolic dysfunction. A 2020 systematic review in Fertility and Sterility found that women with PCOS have significantly higher rates of subclinical cardiac dysfunction compared with weight-matched controls. Retatrutide's weight loss and insulin-sensitizing effects are theoretically attractive in this group, but no PCOS-specific cardiac data exist for this drug.

If you have PCOS and are in your reproductive years, two additional issues arise: first, dramatic weight loss on retatrutide may restore ovulation unexpectedly, creating pregnancy risk if you are sexually active with a male partner. Second, retatrutide is absolutely contraindicated in pregnancy, meaning reliable contraception is non-negotiable from the first dose.

Perimenopause: The Highest-Risk Window

The menopausal transition drives rapid changes in body fat distribution (toward central/visceral adiposity), arterial stiffness, and diastolic function. Women in perimenopause who already carry metabolic risk factors are the demographic most likely to develop HFpEF over the following decade. The SWAN Heart Study documented that cardiac structure and function change measurably during the menopausal transition, independent of chronological age.

For perimenopausal women considering off-label retatrutide, the clinical logic for weight loss to protect cardiac function is reasonable, but note that this group also has the highest likelihood of irregular cycles that mask early pregnancy. Sensitive pregnancy testing before each dose escalation is appropriate.

Postmenopause

Postmenopausal women do not carry pregnancy risk, which simplifies one dimension of management. However, they are at highest absolute risk of HFpEF and may be on multiple cardiovascular medications, creating drug-drug interaction considerations. Diuretics used for heart failure combined with retatrutide's nausea-induced fluid restriction can precipitate acute kidney injury. Dose escalation should be slower in this group, and electrolytes should be monitored more frequently.

Pregnancy, Lactation, and Contraception: Required Reading Before You Start

Retatrutide is contraindicated in pregnancy. This is not a precautionary hedge. Animal reproductive toxicology studies show dose-dependent fetal harm including embryolethality and skeletal anomalies at exposures relevant to human doses. No human pregnancy safety data exist. The drug has a long half-life of approximately 6 days, meaning it persists in your body for weeks after the last dose.

The WomanRx recommendation, consistent with guidance applied to other GLP-1 agonists per ACOG's framework for weight-affecting medications in reproductive-age women: stop retatrutide at least 2 months before attempting to conceive. Because the drug is not yet approved and no specific washout guidance exists in an FDA label, this 2-month window is a conservative estimate based on approximately 5 to 7 half-lives of clearance.

Effective contraception is mandatory for any woman of reproductive potential starting retatrutide off-label. Options include:

• Combined oral contraceptive pills (noting that GLP-1 agonists may slow gastric emptying, which could theoretically reduce oral contraceptive absorption at peak nausea periods; use a barrier backup during vomiting episodes)
• Intrauterine device (hormonal or copper): unaffected by GI motility changes and the most reliable option
• Implant

Lactation: There are no human data on retatrutide transfer into breast milk. Given the absence of safety data and the drug's large molecular weight as a peptide, the risk is theoretically low for systemic infant absorption if any transfer occurs, but "theoretically low" is not the same as "safe." The WomanRx position is that retatrutide should not be used during lactation until human milk transfer data are available.

Who This Is Right For, and Who Should Not Use Retatrutide Off-Label for Heart Failure

Potential Candidates (All Criteria Must Apply)

A woman might reasonably discuss off-label retatrutide for cardiac-related weight management if she:

• Has HFpEF with an obesity driver (BMI >35 kg/m² contributing to symptoms)
• Has failed or cannot tolerate semaglutide or tirzepatide
• Is not pregnant and is using reliable contraception, or is postmenopausal
• Has no personal or family history of medullary thyroid carcinoma or MEN2
• Has stable, not decompensated, heart failure (NYHA Class I or II)
• Is under the care of both a cardiologist and a prescribing clinician who will coordinate the monitoring protocol above
• Understands and accepts the experimental nature of this use, documented in a shared decision-making note

Women Who Should Not Use Retatrutide Off-Label for Heart Failure

Do not use retatrutide off-label for heart failure if you:

• Are pregnant, planning pregnancy within 2 months, or breastfeeding
• Have decompensated heart failure or NYHA Class III-IV symptoms
• Have a personal or family history of MTC or MEN2A/2B
• Have a resting heart rate above 90 bpm at baseline without a reversible cause
• Have a history of pancreatitis (class risk for GLP-1-containing agents)
• Have severe renal impairment (eGFR <30 mL/min/1.73m²)
• Have active gallbladder disease (rapid weight loss increases gallstone risk)

The Evidence Gap: What Is Missing for Women Specifically

Women represent roughly half of the population but have been systematically under-represented in cardiovascular drug trials for decades. The retatrutide Phase 2 trial enrolled approximately 338 participants, and sex-stratified efficacy and safety data were not reported in the primary publication. We do not know whether women lose more or less weight than men on retatrutide (as has been observed with some GLP-1 agents), whether the heart rate effect is larger in women, or whether the rate of common side effects like nausea differs by sex.

A 2023 analysis in JAMA Network Open found that women are still significantly under-represented in obesity pharmacotherapy trials despite carrying a higher global burden of obesity. Until Phase 3 retatrutide trial data are published with sex-stratified sub-analyses, any statement about retatrutide's cardiac effects specifically in women is extrapolation from the full-trial population.

This is not a reason to refuse to discuss the drug. It is a reason to demand sex-disaggregated reporting and to interpret available data with appropriate caution.

Current Phase 3 Trial Field and What to Watch For

As of early 2025, Eli Lilly has announced Phase 3 trials for retatrutide in obesity (the TRIUMPH program). A dedicated cardiovascular outcomes trial (CVOT) has not been announced publicly for retatrutide specifically, though the FDA now requires CVOTs for weight-loss drugs. GLP-1 class cardiovascular benefits have been shown for semaglutide in the SELECT trial, which enrolled over 17,000 participants with pre-existing cardiovascular disease and found a 20% relative risk reduction in major adverse cardiovascular events with 2.4 mg semaglutide over a mean follow-up of 34.2 months. Whether a triple agonist like retatrutide replicates or exceeds that signal is a genuinely open question.

The SELECT trial did enroll women, but only 27.5% of participants were female, which the trial investigators acknowledged as a limitation. For retatrutide's eventual CVOT, advocacy for at least 45% female enrollment is warranted and is something the WomanRx editorial board supports explicitly.

Practical Questions to Ask Your Clinician

Before agreeing to off-label retatrutide for heart-failure-related weight management, ask your prescribing clinician these specific questions:

1. Where is this drug coming from? (Compounding pharmacy vs. Clinical trial vs. Other? Understand the sourcing and quality assurance.)
2. Which cardiologist will be co-managing my care, and how will they receive my monitoring results?
3. What specific target do we have for NT-proBNP or echocardiographic improvement, and at what point do we stop if we do not see it?
4. What is the dose escalation schedule, and can we go slower given my heart failure diagnosis?
5. If I experience worsening shortness of breath or edema, what is the protocol?

WomanRx editorial board member and obesity medicine specialist Dr. Elena Vasquez states: "The weight loss data for retatrutide are genuinely impressive, and the mechanistic case for benefit in HFpEF is plausible. But right now, we are asking women to accept experimental risk on the basis of inference. That is a conversation that requires full transparency, a cardiologist in the loop, and a monitoring plan that is written down before the first injection is given."